SELURAMPANEL

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H19N5O4S
Molecular Weight	377.418
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C1=C(C=C2C(=O)N(NS(C)(=O)=O)C(=O)NC2=C1)C3=CC=NN3C

InChI

InChIKey=MCECSFFXUPEPDB-UHFFFAOYSA-N

InChI=1S/C16H19N5O4S/c1-9(2)10-8-13-12(7-11(10)14-5-6-17-20(14)3)15(22)21(16(23)18-13)19-26(4,24)25/h5-9,19H,1-4H3,(H,18,23)

HIDE SMILES / InChI

Molecular Formula	C16H19N5O4S
Molecular Weight	377.418
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24147649 | https://www.ncbi.nlm.nih.gov/pubmed/27610084 | https://www.ncbi.nlm.nih.gov/pubmed/23963355

Selurampanel (previously known as BGG 492), an orally available, AMPA-type glutamate receptor (AMPAR)/kainate receptor (GluK1; GluR5) antagonist was developed by Novartis. It is known that AMPAR antagonism is under development as a novel mechanism of action for antiepileptic drugs. Selurampanel was studied in phase II clinical trial for the migraine treatment. However, Proof-of-concept criterion was not met. In addition, the drug also participated in phase II clinical trials in therapy-refractory partial seizures for epilepsy surgery and in patients with chronic subjective tinnitus. Development of selurampanel for all these diseases was discontinued as of September 2017.

Originator

Approval Year

PubMed

Title	Date	PubMed
Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist.	2017-02-03	27863026
Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks.	2014-02	23963355
BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy.	2014-01	24147649

Patents

Sample Use Guides

In Vivo Use Guide

BGG492 (SELURAMPANEL) (250 mg), vs placebo and sumatriptan (100 mg), in 75 subjects with acute migraine attacks

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:43:47 GMT 2025` Edited by `admin` on `Mon Mar 31 19:43:47 GMT 2025`
Record UNII	7WG1MR7DAR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SELURAMPANEL

Official Name

English

selurampanel [INN]

Preferred Name

English

BGG-492

Code

English

N-(6-(1-METHYL-1H-PYRAZOL-5-YL)-7-(PROPAN-2-YL)-2,4-DIOXO-1,4-DIHYDROQUINAZOLIN-3(2H)-YL)METHANESULFONAMIDE

Systematic Name

English

BGG492

Code

English

Selurampanel [WHO-DD]

Common Name

English

METHANESULFONAMIDE, N-(1,4-DIHYDRO-7-(1-METHYLETHYL)-6-(1-METHYL-1H-PYRAZOL-5-YL)-2,4-DIOXO-3(2H)-QUINAZOLINYL)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C264